BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu J, Chen Y, Li R, Wu Z, Xu Q, Li Z, Annane D, Feng H, Huang S, Guo J, Zhang L, Ye X, Zhu W, Du H, Liu Y, Wang T, Chen L, Wen Z, Teboul JL, Chen D. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study. Clin Microbiol Infect 2021:S1198-743X(21)00234-2. [PMID: 34020032 DOI: 10.1016/j.cmi.2021.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Zhang Y, Lu L, Li X, Wu Y, Yang Y, Li T, Cao W. Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1116738] [Reference Citation Analysis]
2 Marcec R, Dodig VM, Radanovic I, Likic R. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol 2022;:e2397. [PMID: 36097650 DOI: 10.1002/rmv.2397] [Reference Citation Analysis]
3 Chen Y, Xie J, Wu W, Li S, Hu Y, Hu M, Li J, Yang Y, Huang T, Zheng K, Wang Y, Kang H, Huang Y, Jiang L, Zhang W, Zhong M, Sang L, Zheng X, Pan C, Zheng R, Li X, Tong Z, Qiu H, Weng L, Du B. Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study. Front Immunol 2021;12:738532. [PMID: 35154067 DOI: 10.3389/fimmu.2021.738532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Salehi M, Barkhori Mehni M, Akbarian M, Fattah Ghazi S, Khajavi Rad N, Moradi Moghaddam O, Jamali Moghaddam S, Hosseinzadeh Emam M, Abtahi SH, Moradi M, Ghiasvand F. The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study. Eur J Med Res 2022;27:18. [PMID: 35115056 DOI: 10.1186/s40001-022-00637-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Focosi D, Franchini M, Tuccori M, Cruciani M. Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. Vaccines (Basel) 2022;10:94. [PMID: 35062755 DOI: 10.3390/vaccines10010094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 López-Medrano F, Aguado JM. Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy? Clin Microbiol Infect 2021:S1198-743X(21)00403-1. [PMID: 34325068 DOI: 10.1016/j.cmi.2021.07.012] [Reference Citation Analysis]